Evaxion A/S EVAX
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $7.53M, +125.1% YoY · Filed Mar 5, 2026
Evaxion A/S (EVAX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.5 million and a net loss of $7.7 million. Free cash flow was -$6.6 million. As of Dec 31, 2025 it held $23.2 million in cash and investments and $7.5 million in total debt.
Revenue
$7.53M
+125.1% vs prior year
Net income
$-7.71M
+27.1% vs prior year
Operating cash flow
$-6.62M
+48.8% vs prior year
Free cash flow
$-6.64M
+48.7% vs prior year
EPS
$-0.81
+17.3% vs prior year
Dividend per share
None
Shares outstanding
417.01M
+494.6% vs prior year
Net cash
$15.73M
FY 2025
Operating margin
-122.7%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EVAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Denmark
- Headquarters
- Hoersholm
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1828253
- Former names
- Evaxion Biotech A/S (until May 5, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.5M | $3.3M | $73,000 | — | — |
| Operating income | -$9.2M | -$14.7M | -$22.2M | -$25.3M | -$25.8M |
| Net income | -$7.7M | -$10.6M | -$22.1M | -$23.2M | -$24.5M |
| Diluted EPS | — | — | -$0.81 | -$0.98 | -$1.26 |
| Operating cash flow | -$6.6M | -$12.9M | -$17.7M | -$25.8M | -$21.9M |
| Free cash flow | -$6.6M | -$12.9M | -$17.8M | -$26.1M | -$23.2M |
| Total assets | $28.4M | $12.5M | $12.9M | $22.0M | $40.2M |
| Total liabilities | $11.4M | $14.1M | $17.6M | $13.7M | $7.7M |
| Stockholders' equity | $17.0M | -$1.7M | -$4.7M | $8.3M | $32.4M |
| Cash and investments | $23.2M | $6.0M | $5.6M | $13.2M | $32.2M |
| Total debt | $7.5M | $10.1M | $10.9M | $10.3M | $3.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 4, 2026 |
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 4, 2026 |
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 30, 2026 | Oct 30, 2026 |
| 6-K | Current report (foreign issuer) | Oct 23, 2026 | Oct 23, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
All 364 Evaxion A/S SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.